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Abstract The purpose of this prospective study is to
evaluate the efficacy and limitations of two-session
Gamma Knife radiosurgery (GKS) alone for large meta-
static brain tumors. Inclusion criteria were as follows:
(i) patients with large metastatic brain tumors (volume
[15 cm3 in the supratentorial region or [10 cm3 in the
infratentorial region), and (ii) tumors not causing clinical
signs of impending cerebral herniation. Twenty-eight
lesions in 27 consecutive patients (18 men and 9 women,
age range 32 to 88 years, median age 65 years) were
included in this study. The radiosurgical protocol was as
follows: 20–30 Gy given in two fractions 3–4 weeks apart.
The local tumor control rate and the overall survival rate
were calculated by using the Kaplan–Meier method.
Median tumor volumes were 17.8 cm3 at first GKS and
9.7 cm3 at second GKS. Median follow-up time was
8.9 months. The local control rate was 85 % at 6 months
and 61 % at 12 months. The overall survival rate after
GKS was 63 % at 6 months and 45 % at 12 months. The
1-year rate of prevention of neurological death was main-
tained at 78 %. Mean Karnofsky performance status (KPS)
improved from 61 [95 % confidence interval (CI), 57–71]
at first GKS to 80 (95 % CI, 74–85) at second GKS; the
best follow-up mean KPS was 85 (95 % CI, 78–91)
(p \ 0.001). Local tumor recurrence necessitated craniot-
omy in two patients and repeat GKS in three patients.
Seventeen patients died, and the causes of death were as
follows: 3 from local progression, 2 from meningeal car-
cinomatosis, and 12 from progression of the primary tumor.
Delayed symptomatic perilesional edema developed in one
patient and eventually resolved with conservative treat-
ment. Two-session GKS for large brain metastases appears
to be an effective treatment in terms of both local tumor
control and neurological palliation with minimal treatment-
related morbidity. These data suggest that two-session
GKS could be used as an alternative to surgical resection of
large tumors in patients with significant comorbidity and/or
at an advanced age. The optimum regimen for dose and
fraction schedule remains to be established.
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Introduction
Stereotactic radiosurgery (SRS) has become a treatment
option of choice for the management of brain metastases
[1–3]. Patients are generally considered candidates for SRS
if their tumors are less than 10 cc in volume (\3 cm
average diameter). Large-volume tumors have not hitherto
been considered suitable for SRS because tumor size cor-
relates with decreased response rate to radiation and
increased risk of neurotoxicity [4, 5]. Standard treatment
for large metastatic brain tumors is surgical resection, with
adjuvant radiotherapy if feasible [5–8]. The number of
patients with large brain metastases who are eligible for
craniotomy is, however, fairly limited because of surgical
accessibility of the tumor, the number of lesions, and the
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extent of systemic disease. Hypofractionated stereotactic
radiation therapy (SRT) has been an alternative to improve
the therapeutic ratio between tumor control and adverse
radiation effects for treating large brain metastases [9–11].
Higuchi et al. [12] reported a new treatment method, where
three-session stereotactic radiotherapy using Gamma Knife
achieved excellent treatment results, presumably by virtue
of significant tumor volume reduction during the inter-
fraction intervals. The authors subsequently developed an
alternative treatment paradigm comprising two-session
GKS for large metastatic brain tumors, and the present




A prospective clinical trial was conducted to evaluate the
efficacy and limitations of two-session GKS for large
metastatic brain tumors. The institutional review board
approved this prospective clinical trial in September 2009.
Inclusion criteria were as follows: (i) patients with large
metastatic brain tumors (volume [ 15 cm3 in the supra-
tentorial region or [10 cm3 in the infratentorial region),
and (ii) tumors not causing clinical signs of impending
cerebral herniation. The patients and/or their relatives were
fully informed of the efficacy, invasiveness, and limitations
of both radiosurgery and surgical resection; all gave written
informed consent.
From October 2009 to April 2011, 30 consecutive
lesions in 29 patients (20 men and 9 women) were enrolled
in the present study, but 2 of these were excluded because
the treatment protocol could not be completed (one due to
acute lethal pancreatitis and the other to progression of
systemic disease). Thus, 27 patients with 28 lesions were
included in the study. The age range was from 32 to
88 years (median 65 years). In all cases, the diagnosis of
the primary lesion had been confirmed histopathologically.
Among patients harboring large metastatic tumors, six had
undergone resective surgery before two-session GKS, three
had had Ommaya reservoirs inserted, and two had already
undergone whole-brain radiation therapy (WBRT) at their
referring hospital.
Radiosurgical techniques
GKS was performed using the Leksell G stereotactic frame
(Elekta Instruments, Stockholm, Sweden). The frame was
placed on the patient’s head under local anesthesia and
with mild sedation. All patients underwent both stereotactic
magnetic resonance (MR) imaging and computed tomog-
raphy (CT). High-resolution three-dimensional (3-D) vol-
umetric gadolinium-enhanced T1-weighted images and
2-mm-thick T2-weighted images were used for dose
planning with Leksell Gamma Plan software (Elekta
Instruments). The planning target volume was defined by
adding no margin to the gross tumor volume. An isodose of
less than 50 % was employed in most cases. At the end of
the dose planning, spatial distortion of the MR scans was
meticulously corrected for by checking CT images against
MR images. The fraction protocol was as follows:
20–30 Gy in two fractions with 3–4 weeks between frac-
tions. The interval between radiosurgical sessions was
usually 3 weeks, but in some patients it was necessary to
postpone the second procedure due to the schedule of
concomitant systemic chemotherapy. The fractionated dose
was calculated by using a linear quadratic formula, as
described by Brenner et al. [13]. Assuming alpha/beta to be
10 for brain metastases, 20–30 Gy in two fractions was
approximately equivalent to a single administration of
16–23 Gy. The Leksell Model C Gamma Knife was used
in all cases. Concomitant small- to medium-sized metas-
tases were also treated with SRS at a prescription dose
ranging from 18 to 22 Gy (median 20 Gy) at either the first
or the second session. Patient characteristics, tumor loca-
tion, and treatment prior to two-session GKS are presented
in Table 1.
Post-GKS management and follow-up evaluation
In patients with significant neurological symptoms, admin-
istration of oral steroids (usually dexamethasone 2 mg per
day) was continued between the two sessions and was
tapered off and discontinued over a maximum of 4 weeks
after the second session. Clinical follow-up comprised
neuroradiological evaluation of bimonthly MR images as
well as neurological evaluation, including KPS, in order to
provide early identification of local and distant tumor
recurrences. The change in tumor volume was calculated
from 3-D volumetric MR images. Local control failure was
defined as an increase in target lesion volume of at least
20 % compared with the smallest documented tumor vol-
ume on MRI. Delayed radiation injury was cautiously
differentiated from tumor recurrence using the T1/T2
mismatch method [14] and the signal–intensity time curve
obtained from dynamic susceptibility-weighted contrast-
enhanced perfusion MR imaging [15]. Additional GKS was
possible in principle, provided the volume of local tumor
recurrence was small enough for single-session SRS. Sur-
gical removal was indicated when clinical signs of cerebral
herniation developed, with a radiological diagnosis of local
tumor progression or radiation necrosis. Any adverse
events attributable to SRS were evaluated by National
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Cancer Institute Common Terminology Criteria for
Adverse Events (CTCAE) version 4.03. Patients with
symptomatic delayed radiation injury were treated with
intensive oral steroids and hyperbaric oxygen therapy [16].
When metachronous brain metastases were shown as
small-enhanced lesions in serial MR imaging, they were
managed with additional SRS. Neurological death was
defined as death attributable to intracranial metastases,
including tumor recurrence and carcinomatous meningitis.
Statistical analysis
The date of data analysis was October 21st 2011. The local
tumor control rate and the overall survival rate were cal-
culated by using the Kaplan–Meier method. The intervals
from the date of the first intervention for brain metastases
until the date of confirmed local control failure or the date
of death were calculated. The rate of prevention of neu-
rological death was similarly calculated with the interval
from the date of the first GKS until the date of neurological
death. Death due to extracranial progression was regarded
as a ‘‘censoring’’ in the estimation of the rate of prevention
of neurological death. In order to assess the impact of this
treatment on the quality of life of patients, the KPSs at each
clinical stage were compared by using the Friedman test.
All statistical analyses were performed with commercially
available statistics software (Prism, version 5.0; GraphPad,
La Jolla, CA). A p value of \0.05 was considered statis-
tically significant.
Results
Median tumor volume was 17.8 cm3 (range 10.0–53.3 cm3).
The median prescription dose at the tumor margin for the
first intervention was 13.3 Gy (range 10–16 Gy), and the
median marginal isodose was 42 % (range 40–50 %).
Similarly in the second intervention, the median prescription
dose at the tumor margin was 13.3 Gy (range 10–15 Gy) and
the median marginal isodose was 44 % (range 40–60 %).
Median tumor volume was 9.7 cm3 at the time of the second
GKS (46 % volume reduction). With the exception of one
case, the tumor volume was reduced at the second session
compared with the original volume.
Median follow-up time was 8.9 months (range
1–21 months). Six patients (21 %) showed failure of local
control between 1 and 13 months after two-session GKS
(median 6.2 months). The local control rate was 85 % and
61 % at 6 and 12 months, respectively (Fig. 1). The overall
survival rate after GKS was 63 and 45 % at 6 and
12 months, respectively. Median survival time was
11.9 months (95 % CI, 4.67–15.63 months) (Fig. 2). Sim-
ilarly, the rate of prevention of neurological death after
GKS was 90 and 78 % at 6 and 12 months, respectively
(Fig. 2).
Follow-up neurological evaluation showed improvement
of 20 or more points on the KPS in 17 patients (61 %), in
terms of motor weakness, seizures, and higher brain
functions. In the other cases (36 %), with the exception of
one patient, the pre-existing neurological deficit remained
Table 1 Patient characteristics
Characteristic Value
Total no. of patients 27
Men/women 18/9
Age (years), median (range) 65 (32–88)












Colon and rectum 4
Esophagus 1
Ovary 1




RTOG Radiation Therapy Oncology Group, RPA recursive parti-
tioning analysis, GKS Gamma Knife surgery, WBRT whole-brain
radiation therapy
Fig. 1 Local tumor control rate
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stable. Mean KPS improved from 61 (95 % CI, 57–71) at
first GKS to 80 (95 % CI, 74–85) at second GKS and 85
(95 % CI, 78–91) at best follow-up time (p \ 0.001,
Friedman test).
Seventeen patients died during follow-up, and the causes
of death were as follows: 3 of intracranial local progres-
sion, 2 of meningeal carcinomatosis, and 12 of progression
of the primary lesion. Subsequent interventions were
needed in 13 cases. Salvage surgical resection was carried
out in two patients because of increasing size of the
metastasis. One patient underwent surgical resec-
tion 2 weeks after the second session because of progres-
sive left hemiparesis; the resection specimen revealed
tumor progression. His neurology was unchanged postop-
eratively. Another patient underwent craniotomy 5 months
after two-session GKS, and histopathology confirmed
predominantly radiation necrosis but with some viable
tumor cells seen. Repeat GKS was performed for 4 local
tumor recurrences in 3 patients, and for new distant
metastases in 11 patients. Local control was achieved in all
recurrent tumors treated with additional procedures.
Two patients had transient emesis, both of whom
required brief hospitalization for steroid administration
(CTCAE grade 3 toxicity). These patients recovered to
their preradiosurgical functional status within 1 week. In
one patient, T2-weighted MR imaging 4 months after the
first intervention demonstrated a high-intensity area in the
surrounding brain stem, suggestive of delayed radiation
toxicity, resulting in neurological deterioration, including
hemiparesis (CTCAE grade 3 toxicity). These neurological
and radiological changes eventually improved with oral
steroids (Fig. 3). Treatment results are summarized in
Table 2.
Fig. 2 Overall survival rate and rate of prevention of neurological
death
Fig. 3 A 72-year-old man with small cell lung cancer presented with
reduced conscious level. MR imaging demonstrated a large necrotic
metastatic brain tumor in the pons. Due to the severity of neurological
symptoms, the risk of WBRT was rated as high. As an alternative
treatment option, the patient was allocated to two-session GKS. The
first treatment delivered 10 Gy to the 40 % isodose (Fig. 3a). Three
weeks later, at the second session, significant tumor volume reduction
was observed and 10 Gy to the 40 % isodose was delivered to the
tumor margin (Fig. 3b). Follow-up MR imaging after 4 months
showed a considerable decrease in tumor size but brain stem perifocal
edema (Fig. 3c). The perifocal edema subsided by the 8-month
follow-up (Fig. 3d), and the KPS improved from 30 to 70. Although
transient neurological deterioration occurred due to delayed radiation
injury, the patient could lead an independent life until 2 months
before he died from systemic disease progression
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Discussion
Surgical resection is a standard treatment option for large
brain tumors. However, surgical resection for metastatic
brain tumors in eloquent locations (primary motor cortex,
thalamus, brain stem) carries significant neurological risk,
even with modern neurosurgical techniques. Other factors
such as patient age, comorbidity, and short life expectancy
may make invasive treatment unattractive.
Single-session radiosurgery is suitable for small tumors,
ideally those which are less than 3 cm in diameter or
10 cm3 in volume. Single-session radiosurgery for large
tumors has the significant disadvantage of a narrow ther-
apeutic ratio. To avoid radiation-induced complications for
large lesions, the dose for a single irradiation may have to
be limited to below the dose needed for effective tumor
control; therefore, dose fractionation is a potential alter-
native strategy for increasing the total dose delivered to the
lesion. Recent studies have found that hypofractionated
SRT for brain metastases can achieve satisfactory tumor
control [10, 17]. Higuchi et al. [12] developed a unique
fraction schedule using Gamma Knife, which differed
significantly from the schedules in the aforementioned
studies, where favorable tumor control was achieved with
three fractions separated by a 2-week interfraction interval.
The advantage of their technique was that it allowed the
radiation dose to normal brain tissue to be reduced for the
second and third treatments owing to continual tumor
volume reduction. In our series, using an interfraction time
of 3–4 weeks, only one tumor was larger at the second
intervention than at the first. From the viewpoint of radi-
ation biology, however, a long interfraction time theoreti-
cally carries a potential concern about ‘‘repopulation’’ of
tumor cell kinetics after radiation. The effects of the repair
of sublethal damage to DNA on the efficacy of treatment
should be taken into account, but parameters to quantify
these effects have not yet been established [18]. The
accumulation and analysis of clinical outcomes should
allow us to determine the clinical effect of a long inter-
fraction time on outcome.
The characteristic benefit of GKS in terms of its inherent
steep radiation fall off can be maintained even in two-
session procedures for larger tumors, thus protecting
adjacent brain tissue from radiation-induced injury. Based
on our own experience and in accordance with the litera-
ture, a marginal dose of 10-15 Gy per fraction is safe and
effective. Moreover, our treatment technique includes
using an intentionally low equivalent isodose at the margin
of the tumor. This strategy means that a high average dose
is delivered inside the target volume while minimizing the
radiation dose to the ‘‘radiation penumbra,’’ which includes
the surrounding brain tissue. Early significant tumor vol-
ume reduction with this approach could provide substantial
neurological palliation with minimal invasiveness, even for
patients with significant comorbidity and/or low perfor-
mance status. GKS as two-session treatment seems to be
associated with a low risk of complications and requires
only a short period of hospitalization compared with both
surgery and WBRT.
Local control of large metastatic lesions was not
achieved even after two-session GKS in six patients
(21 %). This number appears no better than in other pre-
vious studies, which may be attributed to a definition of
local control failure different from in other series. The
present study used the response evaluation criteria in solid
tumors (RECIST) guidelines, because immediate salvage
GKS was preferred if close clinical and imaging monitor-
ing led to early detection of local recurrence or new
lesions. The RECIST definition was much stricter than in
most other studies, which usually define local recurrence as
an increase in size of 25 % or more compared with pre-
treatment size [12, 19]. Even after carefully considering the
difference of criteria used for evaluating local control
failure, the resulting local tumor control in the present
study was not the same as that of single-session SRS for
small to medium-sized brain metastases. Tumor volume
has been proved by many investigators to be a predictive
factor for local tumor control after SRS [20–22], which
would be one of the inevitable limitations of our treatment
approach. Of six patients with local recurrence, three
Table 2 Treatment results and outcome in 27 patients after two-





1-Year local control rate 61
1-Year overall survival rate 45
1-Year rate of prevention of
neurological death
78
Mean KPS (95 % CI)
At first GKS 61 (57–71)
At second GKS 80 (74–85)
Best in follow-up 85 (78–91)
Local recurrence 5
Symptomatic radiation injury 1
Distant new metastases 11
Subsequent treatment
Craniotomy for local recurrence 2
GKS for local recurrence 3
GKS for new metastases 11
Cause of death
Systemic disease progression 12
CNS progression 5
GKS Gamma Knife surgery, CI confidence interval, KPS Karnofsky
performance scale, CNS central nervous system
J Neurooncol (2012) 109:159–165 163
123
underwent salvage GKS procedures, resulting in successful
tumor control in all cases. New intracranial metastases
appeared after two-session GKS in 11 patients (41 %).
These metachronous lesions were managed as described
above. Thus, neurological death could be avoided in many
patients by active continued management of intracranial
metastases. There was, however, a limitation in this type of
local treatment. It is difficult to control meningeal
spreading of metastasis by using stereotactic irradiation
alone. WBRT should be considered as a possible salvage
treatment when carcinomatous meningitis develops.
Overall survival in this series was not found to be better
than in other studies of SRS for brain metastases [12, 19, 23].
All of our patients were in RPA class II or III [24]. There
were no RPA class I patients in this cohort. Given that
prognosis is strongly related to RPA class, our treatment
results are comparable to those of other series [24–26].
We had one complicated case with delayed radiation
toxicity (Fig. 3). In this case, the signal changes on MR
imaging were fortunately reversible and the patient even-
tually recovered to their pre-intervention neurological
level, although their quality of life was significantly
affected for a period of time by this complication. Even
with this treatment technique, it appears to be difficult to
avoid radiation side-effects completely when treating
highly radiosensitive regions such as the brainstem.
One of the reasons behind the introduction of two-session
treatment is related to economic constraints. The public
health insurance system in our country will fund GKS as a
single-session radiosurgical treatment but does not currently
approve a two- or three-session treatment method. The sec-
ond session has to be conducted free of charge. Consequently
two-session GKS method delivers cost-effective medical
care because this treatment costs approximately 20 % less
than other LINAC-based fractionated SRT modalities in our
domestic medical systems. Time constraints for patients with
poor prognosis should also be taken into account. Two-ses-
sion GKS takes less time than other radiotherapeutic
modalities for brain metastasis, which is attractive and
beneficial for patients with advanced cancer.
Conclusions
Two-session Gamma Knife radiosurgical treatment for
large brain metastases represents a safe treatment modality
providing neurological palliation in the short to medium
term, with acceptable tumor control rates and low mor-
bidity. This treatment method can also be used for large
tumors in eloquent locations either after WBRT or as the
primary treatment for patients who are not suitable for
surgical resection. The optimum regimen for dose and
fraction schedule remains to be elucidated.
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